Left atrial appendage occlusion

Intracardiac Echocardiography Devices Market size to grow by USD 11.5 billion from 2022 to 2030; Increasing number of heart-related medical conditions and treatments to boost the market growth - Facts & Factor

Retrieved on: 
Wednesday, June 28, 2023
Heart, Ventricular septal defect, Mayo Clinic, Left atrial appendage occlusion, Life, ICE, Catheter, Hospital, Philips, Patient, Investment, Electrophysiology, TEE, Universal health care, UHC, Growth, Clinical professor, Medical imaging, Health care

Global Intracardiac Echocardiography Devices Market: Growth Drivers

Key Points: 
  • Global Intracardiac Echocardiography Devices Market: Growth Drivers
    Increasing number of heart-related medical conditions and treatments to propel market growth.
  • The global intracardiac echocardiography devices market is projected to grow owing to the increasing number of patients suffering from heart-related conditions and their subsequent treatment.
  • Most traditional tools like transoesophageal echocardiography (TEE) are used to prepare for and act as guiding tools during interventional treatment.
  • Global Intracardiac Echocardiography Devices Market: Segmentation
    The global intracardiac echocardiography devices market is segmented based on end-user, application, and region.

Intracardiac Echocardiography Devices Market size to grow by USD 11.5 billion from 2022 to 2030; Increasing number of heart-related medical conditions and treatments to boost the market growth - Facts & Factor

Retrieved on: 
Wednesday, June 28, 2023
Heart, Ventricular septal defect, Mayo Clinic, Left atrial appendage occlusion, Life, ICE, Catheter, Hospital, Philips, Patient, Investment, Electrophysiology, TEE, Universal health care, UHC, Growth, Clinical professor, Medical imaging, Health care

Global Intracardiac Echocardiography Devices Market: Growth Drivers

Key Points: 
  • Global Intracardiac Echocardiography Devices Market: Growth Drivers
    Increasing number of heart-related medical conditions and treatments to propel market growth.
  • The global intracardiac echocardiography devices market is projected to grow owing to the increasing number of patients suffering from heart-related conditions and their subsequent treatment.
  • Most traditional tools like transoesophageal echocardiography (TEE) are used to prepare for and act as guiding tools during interventional treatment.
  • Global Intracardiac Echocardiography Devices Market: Segmentation
    The global intracardiac echocardiography devices market is segmented based on end-user, application, and region.

Study Demonstrates Successful Device Size Selection When Assessing Left Atrial Appendage by Angiography Compared to TEE

Retrieved on: 
Monday, February 27, 2023
Left atrial appendage occlusion, Angiography, CLAAS, Safety, EFS, Ventricular fibrillation, Risk, FDA, Patient, LAA, CRT, Conference, Food and Drug Administration, Thomas Jefferson University, Dartmouth, Stroke, TEE, Atrial fibrillation, Food, Anticoagulant, Physician, Medical device, Medicine

NASHUA, N.H., Feb. 27, 2023 /PRNewswire/ -- Conformal Medical, Inc. announced today the results from the CONFORMAL Early Feasibility Study (EFS), evaluating the use of angiography compared to transesophageal echocardiogram (TEE) for left atrial appendage (LAA) assessment. The findings were presented at this year's Cardiovascular Research Technologies Conference (CRT 2023) in Washington, DC by Dr. William Gray, co-Director of the Lankenau Heart Institute and Professor of Medicine at Thomas Jefferson University during the Left Atrial Appendage Closure Forum.

Key Points: 
  • Data from "Real-Time Atrial Appendage Assessment for LAAO-CLAAS Device Selection: Angiography vs TEE" was presented at Cardiovascular Research Technologies Conference (CRT)
    NASHUA, N.H., Feb. 27, 2023 /PRNewswire/ -- Conformal Medical, Inc. announced today the results from the CONFORMAL Early Feasibility Study (EFS), evaluating the use of angiography compared to transesophageal echocardiogram (TEE) for left atrial appendage (LAA) assessment.
  • "This study evaluated baseline TEE and angiographic data collected from 36 atrial fibrillation (AFib) patients who were deemed appropriate for left atrial appendage occlusion (LAAO)," stated Dr. Gray.
  • "The complete paired images were analyzed for LAA diameter and depth to facilitate CLAAS device size selection.
  • Results demonstrated a 97% agreement in device size selection between the two imaging modalities."

AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial

Retrieved on: 
Tuesday, January 31, 2023
Surgery, Medical Devices, Hospitals, Clinical Trials, Cardiology, Other Health, Health, Pharmaceutical, General Health, McMaster University, Physician, Hospital, Safety, Patient, Elective surgery, NCT, Clinical trial, IDE, Risk, Stroke, FDA, Left atrial appendage occlusion, LAA, Michael G. DeGroote School of Medicine, Pharmaceutical industry, Atrial fibrillation

The patient was treated by U.S. co-principal investigator Dr. Marc Gerdisch at Franciscan St. Francis Heart Center in Indianapolis, Indiana.

Key Points: 
  • The patient was treated by U.S. co-principal investigator Dr. Marc Gerdisch at Franciscan St. Francis Heart Center in Indianapolis, Indiana.
  • The trial will enroll up to 6,500 patients at up to 250 centers worldwide, making it the largest randomized clinical trial for surgical LAA exclusion.
  • PHRI is a clinical research organization that has organized an extensive international network of committed collaborators in 102 countries.
  • “A fantastic multidisciplinary team has designed the trial, and we’re all excited to advance the understanding of atrial disease, atrial fibrillation and stroke.”

Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option

Retrieved on: 
Tuesday, September 6, 2022
Security (finance), Technology, LAA, Securities Exchange Act of 1934, NYSE, Safety, BSX, Securities Act of 1933, Warfarin, Boston Scientific, Food and Drug Administration, Time, Exercise, DAPT, Boston, Risk, Left atrial appendage occlusion, NCDR, CT, Drug Quality and Security Act, Food, Physician, American College, Science, Forward-looking statement, NVAF, FLX, U.S. Securities and Exchange Commission, Aspirin, OAC, Intention, ACCF, FDA, Twitter, Ventricular fibrillation, Intellectual property, Annual report, LAAC, Health, Life, Patient, Pharmaceutical industry, Medical device, Part Two, Facebook, Amulet

MARLBOROUGH, Mass., Sept. 6, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use labeling for the current-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device to include a 45-day dual anti-platelet therapy (DAPT) option as an alternative to 45-day oral anticoagulation (OAC) plus aspirin for post-procedural treatment of patients with non-valvular atrial fibrillation (NVAF).

Key Points: 
  • "This significant step forward is supported by the robust safety and efficacy profile demonstrated by both the legacy WATCHMAN and current-generation WATCHMAN FLX technologies."
  • The labeling in Europe has included the choice of either OAC or a DAPT post-procedural drug regimen for WATCHMAN technology since 2017.
  • Ongoing studies with the WATCHMAN FLX device include the CHAMPION-AF and OPTION clinical trials to evaluate use of the device for broader patient populations with NVAF.
  • Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.

Late Breaking Clinical Trials Announced for HFSA Annual Scientific Meeting 2022

Retrieved on: 
Wednesday, August 31, 2022
Momentum, Pharmacist, Patient, Research, Livestreaming, OnDemand, Left atrial appendage occlusion, Symposia, Heart failure, Late, Registry, Physician, Adrenal insufficiency, PIT, Education, Multimedia, Heart, CHF, ASM, Nursing, Heart Failure Society of America, Practitioner, Health, Pharmaceutical industry

ROCKVILLE, Md., Aug. 31, 2022 /PRNewswire/ -- The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Trials coming to its Annual Scientific Meeting (ASM), which will take place September 30 October 3, 2022, at the Gaylord National Harbor, just outside of Washington, DC.

Key Points: 
  • ROCKVILLE, Md., Aug. 31, 2022 /PRNewswire/ -- The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Trials coming to its Annual Scientific Meeting (ASM), which will take place September 30 October 3, 2022, at the Gaylord National Harbor, just outside of Washington, DC.
  • Late Breaking Clinical Trials is an always-popular session where speakers present the results of new research in heart failure.
  • Featured in back-to-back sessions on Sunday, October 2, Late Breaking Clinical Trials provides exposure and recognition for major randomized trials and registries that will likely have a significant impact on clinical practice or result in significant advances in the field.
  • Due to the quantity of remarkable trials submitted, two Late Breaking Clinical Trials Sessions will take place, with each session providing a deep dive into the latest rapidly evolving research in the field of heart failure.

Ziosoft to Feature ECVct and LAAO Advanced Visualization at American College of Cardiology Annual Convention

Retrieved on: 
Friday, April 1, 2022
Disease, ACC, Heart, Marketing, The San Diego Union-Tribune, TAVR, AV, Coronary CT angiography, Ownership, Left atrial appendage occlusion, Abraxis BioScience, Amyloid, Program, Pathology, Percutaneous aortic valve replacement, Atrial appendage, Man, MD, Woman, ECV, Stroke, American College, ImmunityBio, Coronary, Weeping Angel, Solution, Atrial fibrillation, Amyloidosis, Efficiency, Protein, Patient, CCTA, Decision-making, Medical imaging, NantWorks

NEWARK, Calif., April 1, 2022 /PRNewswire-PRWeb/ -- Ziosoft, a pioneer and leader in 3D/4D advanced visualization, will feature its ECVct (Extracellular Volume Fraction with computed tomography) and LAAO (Left Atrial Appendage Occlusion) advanced visualization (AV) software at the annual American College of Cardiology (ACC) conference being held in Washington DC, April 2-4, 2022. Both capabilities are part of Ziosoft's extensive array of AV solutions for multiple applications and modalities on its flagship Ziostation2 platform.

Key Points: 
  • NEWARK, Calif., April 1, 2022 /PRNewswire-PRWeb/ -- Ziosoft, a pioneer and leader in 3D/4D advanced visualization, will feature its ECVct (Extracellular Volume Fraction with computed tomography) and LAAO (Left Atrial Appendage Occlusion) advanced visualization (AV) software at the annual American College of Cardiology (ACC) conference being held in Washington DC, April 2-4, 2022.
  • In addition to ECVct and LAAO, Ziosoft will be demonstrating its unique PhyZiodynamics 3D/4D solution as well as CT lung resection software.
  • "Zioflex enables a risk free entry into the utilization of highly advanced visualization and analytics contained within the Ziosoft platform," said Taitriya.
  • Ziosoft provides a comprehensive multi-modality, 3D/4D advanced processing and viewing solution for a wide variety of specialties.

BIOMODEX and Montreal Heart Institute Team Up to Develop 3D Printed Pulsatile Heart Models

Retrieved on: 
Wednesday, January 5, 2022
Viscosity, Blood, 3D, Left atrial appendage occlusion, Hospital, Canada Research Chair, Anatomy, Movement, Hemodynamics, Montreal Heart Institute, Patient, Research institute, Cardiology, Physician, Universitate metro station, Institute, MHI, ICE, Friction, CEO, Medicine, Adoption, Pressure, Technology, TEE, Approximation error, Leadership, Medical imaging, Medical device

"Physicians often tell us they are impressed by how well our structural heart solution simulates the feel, friction, and haptic feedback of real heart tissue and blood vessels. Simulating valve movement goes well beyond that -- and will take our solution to the next level. We are essentially delivering a complex system that replicates a beating heart with valves that open and close as blood moves through," said Ziad Rouag, President and CEO of Biomodex. "The team here at Montreal Heart Institute has the expertise to make our vision a reality, and we welcome the opportunity to collaborate."

Key Points: 
  • The models will be used with a specialized station and cardiac pump, allowing the valves to open and close to mimic a beating heart.
  • "Physicians often tell us they are impressed by how well our structural heart solution simulates the feel, friction, and haptic feedback of real heart tissue and blood vessels.
  • "The team here at Montreal Heart Institute has the expertise to make our vision a reality, and we welcome the opportunity to collaborate."
  • "We are excited to develop with Biomodex new cutting-edge training tools that have the potential to reshape how cardiovascular care is delivered."

BIOMODEX and Montreal Heart Institute Team Up to Develop 3D Printed Pulsatile Heart Models

Retrieved on: 
Wednesday, January 5, 2022
Viscosity, Blood, 3D, Left atrial appendage occlusion, Hospital, Canada Research Chair, Anatomy, Movement, Hemodynamics, Montreal Heart Institute, Patient, Cardiology, Physician, Institute, MHI, ICE, Friction, CEO, Medicine, Adoption, GLOBE, Pressure, Technology, TEE, Approximation error, Leadership, Medical device, Medical imaging

“Physicians often tell us they are impressed by how well our structural heart solution simulates the feel, friction, and haptic feedback of real heart tissue and blood vessels. Simulating valve movement goes well beyond that -- and will take our solution to the next level. We are essentially delivering a complex system that replicates a beating heart with valves that open and close as blood moves through,” said Ziad Rouag, President and CEO of Biomodex. “The team here at Montreal Heart Institute has the expertise to make our vision a reality, and we welcome the opportunity to collaborate.”

Key Points: 
  • The models will be used with a specialized station and cardiac pump, allowing the valves to open and close to mimic a beating heart.
  • Physicians often tell us they are impressed by how well our structural heart solution simulates the feel, friction, and haptic feedback of real heart tissue and blood vessels.
  • The team here at Montreal Heart Institute has the expertise to make our vision a reality, and we welcome the opportunity to collaborate.
  • We are excited to develop with Biomodex new cutting-edge training tools that have the potential to reshape how cardiovascular care is delivered.

Conformal Medical Appoints George Fazio to Board of Directors

Retrieved on: 
Thursday, November 19, 2020
LAAC, Atrial appendage, Medical device, Medical devices, Interventional cardiology, Left atrial appendage occlusion

NASHUA, N.H., Nov. 19, 2020 /PRNewswire/ -- Conformal Medical, Inc. , a privately-held medical device company developing next generation left atrial appendage closure (LAAC) technology,today announced the appointment of George Fazio to its board of directors.

Key Points: 
  • NASHUA, N.H., Nov. 19, 2020 /PRNewswire/ -- Conformal Medical, Inc. , a privately-held medical device company developing next generation left atrial appendage closure (LAAC) technology,today announced the appointment of George Fazio to its board of directors.
  • Currently, Mr. Fazio is the president and chief executive officer of Corvia Medical , a medical device company with a first-in-class structural heart device to treat heart failure.
  • "We are very pleased to have George join Conformal's board of directors at this important time as we embark on our U.S. IDE trial," commented Andy Levine, co-founder and chief executive officer of Conformal Medical.
  • Founded in 2016, Conformal Medical, Inc. is a privately held medical device company developing next generation left atrial appendage closure (LAAC) technology.